Relief Therapeutics Holding SA (ETR:RLF)

PRESS RELEASE

published on 10/29/2024 at 07:00, 1 year 4 months ago

Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
Relief Therapeutics announced the publication of a Plain Language Summary on PKU GOLIKE for phenylketonuria management, highlighting findings on prolonged-release protein substitute with similarities to natural proteins

Medical Research Relief Therapeutics PKU GOLIKE Phenylketonuria Plain Language Summary
BRIEF

published on 10/25/2024 at 07:05, 1 year 5 months ago

Relief Therapeutics dévoile les résultats prometteurs d'une étude sur RLF-OD032

Étude Clinique RLF-OD032 Dépôt De Brevet Phénylcétonurie Absorption Des Médicaments
BRIEF

published on 10/25/2024 at 07:05, 1 year 5 months ago

Relief Therapeutics Unveils Promising Study Results for RLF-OD032

Clinical Study Patent Filing RLF-OD032 Phenylketonuria Drug Absorption
PRESS RELEASE

published on 10/25/2024 at 07:00, 1 year 5 months ago

Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
Relief Therapeutics reports positive study results for RLF-OD032, showing superior absorption in fasted state compared to KUVAN®, enabling flexible dosing. New patents filed for innovative PKU treatment

Study Results Relief Therapeutics RLF-OD032 Phenylketonuria Provisional Patents
BRIEF

published on 10/21/2024 at 07:05, 1 year 5 months ago

Relief Therapeutics obtient un brevet européen pour RLF-TD011

Désignation De Médicament Orphelin THÉRAPEUTIQUE DE SECOURS RLF-TD011 Brevet Européen Epidermolyse Bulleuse
BRIEF

published on 10/21/2024 at 07:05, 1 year 5 months ago

Relief Therapeutics Secures European Patent for RLF-TD011

Orphan Drug Designation Relief Therapeutics RLF-TD011 European Patent Epidermolysis Bullosa
PRESS RELEASE

published on 10/21/2024 at 07:00, 1 year 5 months ago

Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
Relief Therapeutics receives Notice of Allowance for European Patent covering RLF-TD011 for Epidermolysis Bullosa wound treatment. The patent will protect RLF-TD011 until 2040 in key European countries, with applications under review in other major markets

Relief Therapeutics RLF-TD011 European Patent Epidermolysis Bullosa Wound Treatment
BRIEF

published on 10/08/2024 at 07:05, 1 year 5 months ago

Relief Therapeutics révèle des résultats prometteurs dans un essai clinique sur l'épidermolyse bulleuse

Essai Clinique THÉRAPEUTIQUE DE SECOURS RLF-TD011 Epidermolyse Bulleuse Diversité Du Microbiome
BRIEF

published on 10/08/2024 at 07:05, 1 year 5 months ago

Relief Therapeutics Reveals Promising Results in Clinical Trial for Epidermolysis Bullosa

Clinical Trial Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Microbiome Diversity
PRESS RELEASE

published on 10/08/2024 at 07:00, 1 year 5 months ago

Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
Relief Therapeutics reports promising preliminary results of RLF-TD011 clinical trial for epidermolysis bullosa, showing reduced Staphylococcus aureus and improved microbiome diversity

Microbiome Clinical Trial Relief Therapeutics RLF-TD011 Epidermolysis Bullosa

Published on 03/26/2026 at 23:00, 1 hour 30 minutes ago

FutureGen Industries Announces Closing of Debt Settlement
Published on 03/26/2026 at 22:05, 2 hours 25 minutes ago

BlackBerry to Announce Fourth Quarter and Fiscal Year 2026 Results on April 9, 2026
Published on 03/26/2026 at 22:00, 2 hours 30 minutes ago

Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project
Published on 03/26/2026 at 22:00, 2 hours 30 minutes ago

Green Bridge Metals Reports Visible Copper Sulfide Mineralization in Initial 2026 Titac Drilling, Duluth Complex Minnesota
Published on 03/26/2026 at 21:00, 3 hours 30 minutes ago

Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity

View all ACCESSWIRE

Published on 03/26/2026 at 20:48, 3 hours 41 minutes ago

Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 5 hours 9 minutes ago

Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:13, 5 hours 16 minutes ago

Director Declaration
Published on 03/26/2026 at 19:09, 5 hours 20 minutes ago

2CRSi SA: Résultats 1er Semestre 2025/26 : Chiffre d'Affaires 204,7 M€ (x9,8) EBITDA de 9,6 M€ (x4,6)
Published on 03/26/2026 at 19:09, 5 hours 20 minutes ago

2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)

View all EQS

Published on 03/26/2026 at 18:17, 6 hours 13 minutes ago

Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 6 hours 13 minutes ago

Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 6 hours 30 minutes ago

Arrêté des comptes au 31 décembre 2025 et perspectives 2026
Published on 03/26/2026 at 18:00, 6 hours 30 minutes ago

Calendrier financier 2026
Published on 03/26/2026 at 18:00, 6 hours 30 minutes ago

LABORATOIRES EUROMEDIS - Fin du contrat de liquidité

View all LES ECHOS COMFI WIRE

News